Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220853 | 1.00 | MAPT (0.62) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2230042 | 1.00 | MAPT (0.62) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2228017 | 0.90 | MAPT (0.52) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2228012 | 0.90 | MAPT (0.52) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL15988228 | 0.85 | ALDH1A1 (0.49) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2228666 | 0.83 | KMT2A (0.68) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL13822539 | 0.79 | MAPT (0.65) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL14634957 | 0.78 | KMT2A (0.75) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL14651035 | 0.78 | MAPT (0.57) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2228184 | 0.77 | KMT2A (0.60) | MAPTTP53KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-01-24 | — | — | US | claimed |
| EP-2523938-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086178-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | disclosed |
| EP-2523938-B1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-01-24 | — | — | US | disclosed |
| EP-2523938-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086178-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | MAPT 704/4885TP53 330/4885KMT2A 2349/4885 |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | MAPT 704/4885TP53 330/4885KMT2A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.